EUVIMEDEUVIMED entdecken
Open Access

Structure-guided engineering of CD112 receptor variants for optimized immunotherapy

Srishti Singh, Estefania Julia, Parismita Kalita, Charlotte Mason, Qianqian Ming, Ansar Lee-Sam, Sumai Gordon, Maria Emilia Buitrago, Daisy W Leung, Patrick Hwu, Vincent C Luca

Molecular Therapy · 2025

DOI: 10.1016/j.ymthe.2025.04.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Srishti Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology Ph.D. Program, University of Sout…. Hauptthemen laut MEDLINE: Immunotherapy, Protein Engineering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immune checkpoint protein, CD112 receptor (CD112R, also known as PVRIG), suppresses T and natural killer (NK) cell activation upon binding to tumor-expressed CD112 (Nectin-2) ligands. Here, we determine the structure of the CD112-CD112R complex and use it to guide the engineering of multiple CD112-targeting immunotherapy candidates. The 2.2 Å-resolution crystal structure reveals an antiparallel, lock-and-key binding mode in which CD112R disrupts CD112 homodimerization. Structural analysis informed directed evolution campaigns focused on remodeling the CD112-CD112R interface, resulting in the isolation of CD112R mutants with greatly increased expression and CD112-binding affinity. The highest-affinity variant, CD112RIVE, potently inhibits CD112-CD112R interactions when utilized as a soluble CD112 trap. Furthermore, incorporating CD112R variants into chimeric antigen receptors (CARs) and T cell engagers (TCEs) leads to more robust T cell activation and killing of CD112+ triple-negative breast cancer (TNBC) cells compared with wild-type CD112R. This strategy demonstrates how structural insights can be leveraged to efficiently generate panels of "affinity-tuned" biologics for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyProtein EngineeringHumansCell Line, TumorProtein BindingReceptors, Chimeric AntigenModels, MolecularLymphocyte ActivationCrystallography, X-RayT-LymphocytesMutationProtein Multimerization

Stichwörter der Autor:innen

CAR T cellsCD112CD112RT cell engagerscheckpoint blockadeimmunotherapyprotein engineeringstructural biology

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL 33612, USA.
  • Department of Clinical Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Electronic address: vince.luca@moffitt.org.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Rita Allen Foundation
  • National Institutes of Health
  • Moffitt Cancer Center

Zitieren

APA

Singh, S., Julia, E., Kalita, P., Mason, C., Ming, Q., Lee-Sam, A., Gordon, S., Buitrago, M. E., Leung, D. W., Hwu, P., & Luca, V. C. (2025). Structure-guided engineering of CD112 receptor variants for optimized immunotherapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.04.032

Vancouver

Singh S, Julia E, Kalita P, Mason C, Ming Q, Lee-Sam A, et al. Structure-guided engineering of CD112 receptor variants for optimized immunotherapy. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.04.032

BibTeX
@article{Singh2025,
  author = {Singh, Srishti and Julia, Estefania and Kalita, Parismita and Mason, Charlotte and Ming, Qianqian and Lee-Sam, Ansar and Gordon, Sumai and Buitrago, Maria Emilia and Leung, Daisy W and Hwu, Patrick and Luca, Vincent C},
  title = {Structure-guided engineering of CD112 receptor variants for optimized immunotherapy},
  journal = {Molecular Therapy},
  year = {2025},
  doi = {10.1016/j.ymthe.2025.04.032}
}
Kostenlos starten →